Related Experiment Video

Updated: Jun 20, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents

Elena V Shashkova1, Shannon M May, Michael A Barry

  • 1Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA.

Virology
|September 22, 2009
PubMed

Insights

Rare adenovirus serotypes Ad6 and Ad11 show promise for oncolytic virotherapy in patients immune to Ad5. These viruses demonstrated safety and efficacy, suggesting their potential as alternatives to Ad5 for cancer treatment.

Area of Science:

  • Oncolytic virotherapy
  • Adenovirus serotypes
  • Cancer treatment

Background:

  • Human adenovirus type 5 (Ad5) is a common platform for oncolytic viruses.
  • Pre-existing immunity to Ad5 can limit its anticancer efficacy.
  • Exploring alternative adenovirus serotypes with low seroprevalence is crucial for improving treatment outcomes.

Purpose of the Study:

  • To evaluate the safety and efficacy of rare adenovirus serotypes (Ad6, Ad11, Ad35) as oncolytic agents.
  • To compare their in vitro and in vivo anticancer activity with Ad5.
  • To investigate potential hepatotoxicity and interactions with Kupffer cells.

Main Methods:

  • In vitro cytotoxicity assays assessing viral activity against cell lines expressing CAR and CD46.
  • In vivo studies in mouse models to evaluate anticancer efficacy.
  • Hepatotoxicity assessment and Kupffer cell interaction studies.

Main Results:

  • In vitro cytotoxicity varied, with Ad5 often more active than Ad6 (CAR-binding) and Ad35 more active than Ad11 (CD46-binding).
  • Ad5, Ad6, and Ad11 showed similar in vivo anticancer activity; Ad35 was not efficacious.
  • Hepatotoxicity was observed only with Ad5; Ad11 and Ad35 pre-dosing did not enhance Ad5 hepatocyte infection.

Conclusions:

  • Ad6 and Ad11 are promising alternative adenovirus serotypes for anticancer treatment.
  • Their distinct interactions with Kupffer cells may influence in vivo behavior.
  • These serotypes offer potential for oncolytic virotherapy in Ad5-immune populations.

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...